A New Option in Hormone Receptor-Positive Breast Cancer: Fulvestrant and Dovitinib

The development of targeted smart drugs has brought personalized treatment to disseminated (stage 4, metastatic) cancers. Hormone-sensitive disseminated breast cancer is a successful example.
Genetic analyses of cancer cells identify features in some patients that may cause treatment resistance from the outset. Approximately %70 of breast cancers are hormone-dependent. In this cancer, hormone-suppressing treatment after a certain period, resistance can develop. Fibroblast growth factor receptor 1 (FGFR1) is a pathway activating tumor growth and allowing cancer cells to evade cell death (the apoptosis pathway). FGFR1 overproliferation may occur in %8 of hormone receptor-positive breast cancers.

The Study A study enrolled menopausal patients previously receiving hormonal treatment whose disease had progressed, with breast cancer diagnosed in 97 participants. Those with overactive FGFR1 received the estrogen receptor suppressor fulvestrant together with the FGFR inhibitor dovitinib .
Dovitinib provided an additional 5,5 months until progression and increased overall response, with no side-effect difference compared with the untreated placebo arm.
This study represents a promising new approach for patients developing hormonal treatment resistance. We will follow future results and American FDA approval processes.
Sources
Phase II, Randomized, Placebo-Controlled Study of Dovitinib in Combination With Fulvestrant in Postmenopausal Patients With HR(+), HER2(−) Breast Cancer That Had Progressed During or After Prior Endocrine Therapy.
Breast Cancer Res 2017 Feb 10;19(1)18
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.